The importance of glucagon receptors in the kidney has been further explored in mice with kidney-specific glucagon receptor knockout (80)
Real-world data shows that many people are using these drugs primarily for weight loss, even if they do not have type 2 diabetes
Clinical outcomes such as cirrhosis progression, liver transplant, and all-cause mortality are recognized as solid endpoints for evaluating drug efficacy in MASLD
Patients with type 2 diabetes already have an elevated baseline risk of pancreatic cancer compared to the general population
Skipping doses or extending dosing intervals can result in appetite rebound, return of cravings, and reduced weight loss momentum
Like, I was like, okay, there's weed and then there's heroin